DG2 Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: understanding NICE guidance
NICE has assessed Elucigene FH20 and LIPOchip to help the NHS decide whether to use these products.
Elucigene FH20 and LIPOchip are tests that detect DNA changes linked to familial hypercholesterolaemia.
NICE has said that Elucigene FH20 and LIPOchip are not recommended for confirming familial hypercholesterolaemia because another test called comprehensive genetic analysis is more likely to accurately confirm the diagnosis at a reasonable cost.
NICE has also said that Elucigene FH20 and LIPOchip are not recommended for testing relatives of people with familial hypercholesterolaemia. Another test called targeted sequencing is more likely to accurately detect familial hypercholesterolaemia in these relatives and is less expensive.
This page was last updated: 20 January 2012